Try Fund Library Premium
For Free with a 30 day trial!
Alternative Equity Focus
Click for more information on Fundata’s FundGrade
Click for more information on Fundata’s FundGrade.
2024
Click for more information on Fundata’s FundGrade
|
NAVPS (06-13-2025) |
$13.63 |
|---|---|
| Change |
-$0.45
(-3.19%)
|
As at May 31, 2025
As at May 31, 2025
Inception Return (April 14, 2021): 7.39%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -8.80% | -19.49% | -30.19% | -19.97% | -26.14% | 7.03% | 13.56% | 7.62% | - | - | - | - | - | - |
| Benchmark | 5.56% | 3.87% | 3.54% | 7.05% | 21.05% | 19.29% | 11.55% | 10.63% | 14.92% | 11.89% | 10.58% | 10.22% | 10.45% | 8.99% |
| Category Average | 3.94% | 0.59% | 0.25% | 2.06% | 8.51% | 12.81% | 7.46% | 5.84% | 9.28% | 7.35% | - | - | - | - |
| Category Rank | 238 / 241 | 226 / 226 | 212 / 212 | 219 / 221 | 188 / 192 | 107 / 149 | 30 / 135 | 48 / 107 | - | - | - | - | - | - |
| Quartile Ranking | 4 | 4 | 4 | 4 | 4 | 3 | 1 | 2 | - | - | - | - | - | - |
| Return % | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -1.46% | 10.88% | 3.45% | 3.34% | -5.45% | -4.19% | -12.78% | 3.90% | -4.32% | -12.22% | 0.57% | -8.80% |
| Benchmark | -1.42% | 5.87% | 1.22% | 3.15% | 0.85% | 6.37% | -3.27% | 3.48% | -0.40% | -1.51% | -0.10% | 5.56% |
14.43% (May 2024)
-12.78% (December 2024)
| Return % | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | - | - | - | - | - | - | - | -1.20% | 30.77% | 26.13% |
| Benchmark | -8.32% | 21.08% | 9.10% | -8.89% | 22.88% | 5.60% | 25.09% | -5.84% | 11.75% | 21.65% |
| Category Average | - | - | - | - | - | 5.11% | 17.27% | -5.96% | 6.54% | 16.58% |
| Quartile Ranking | - | - | - | - | - | - | - | 1 | 1 | 2 |
| Category Rank | - | - | - | - | - | - | - | 30/ 124 | 12/ 142 | 43/ 162 |
30.77% (2023)
-1.20% (2022)
| Name | Percent |
|---|---|
| International Equity | 46.72 |
| US Equity | 44.50 |
| Cash and Equivalents | 8.68 |
| Foreign Government Bonds | 0.10 |
| Name | Percent |
|---|---|
| Healthcare | 89.07 |
| Cash and Cash Equivalent | 8.68 |
| Technology | 2.15 |
| Fixed Income | 0.10 |
| Name | Percent |
|---|---|
| North America | 53.28 |
| Asia | 39.65 |
| Europe | 7.07 |
| Name | Percent |
|---|---|
| Telix Pharmaceuticals Ltd | 20.03 |
| Clarity Pharmaceuticals Ltd | 12.29 |
| Lantheus Holdings Inc | 9.77 |
| Beigene Ltd - ADR | 7.33 |
| RadNet Inc | 6.86 |
| Perspective Therapeutics Inc | 6.39 |
| Danaher Corp | 5.67 |
| Canadian Dollar | 4.74 |
| Amgen Inc | 4.33 |
| SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) | 4.06 |
Portland Life Sciences Alternative Fund Series A
Median
Other - Alternative Equity Focus
| Standard Deviation | 22.66% | - | - |
|---|---|---|---|
| Beta | 0.74% | - | - |
| Alpha | 0.06% | - | - |
| Rsquared | 0.20% | - | - |
| Sharpe | 0.50% | - | - |
| Sortino | 0.88% | - | - |
| Treynor | 0.15% | - | - |
| Tax Efficiency | 100.00% | - | - |
| Volatility |
|
- | - |
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 24.58% | 22.66% | - | - |
| Beta | 1.07% | 0.74% | - | - |
| Alpha | -0.48% | 0.06% | - | - |
| Rsquared | 0.23% | 0.20% | - | - |
| Sharpe | -1.25% | 0.50% | - | - |
| Sortino | -1.37% | 0.88% | - | - |
| Treynor | -0.29% | 0.15% | - | - |
| Tax Efficiency | - | 100.00% | - | - |
| Start Date | April 14, 2021 |
|---|---|
| Instrument Type | Mutual Fund (Alternative) |
| Share Class | Commission Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $14 |
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| PTL320 | ||
| PTL325 | ||
| PTL330 |
The Fund’s objective is to provide positive long-term total returns by investing primarily in a portfolio of securities focused on companies active in the healthcare sector. The Fund may also engage in borrowing for investment purposes. The Fund’s aggregate exposure shall not exceed limits on the use of gross exposure or as otherwise permitted under applicable securities legislation.
The Fund seeks to provide capital growth by primarily investing in a portfolio of equities, ADRs and may also invest in ETFs. The Fund’s investments currently focus on the area of precision oncology. The Fund also may invest in income trusts, debt securities convertible into common stock, convertible and non-convertible preferred stock, debt-like securities and fixed/floating income securities of governments, government agencies, supranational agencies, companies, trusts and limited partnerships
| Portfolio Manager |
Portland Investment Counsel Inc.
|
|---|---|
| Sub-Advisor |
- |
| Fund Manager |
Portland Investment Counsel Inc. |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
CIBC Mellon Global Securities Services Company |
| Distributor |
Mandeville Private Client Inc. |
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | 50 |
| PAC Subsequent | 50 |
| SWP Allowed | Yes |
| SWP Min Balance | 5,000 |
| SWP Min Withdrawal | 50 |
| MER | 2.54% |
|---|---|
| Management Fee | 1.75% |
| Load | Choice of Front or No Load |
| FE Max | 6.00% |
| DSC Max | - |
| Trailer Fee Max (FE) | 1.00% |
| Trailer Fee Max (DSC) | 1.00% |
| Trailer Fee Max (NL) | - |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
For Free with a 30 day trial!
Fund Library
